Compare
20/20 Biolabs, Inc. vs NeoGenomics Inc
| Latest fiscal year | 20/20 Biolabs, Inc. AIDX | NeoGenomics Inc NEO |
|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 |
| Revenue | $2.05M | $727.33M |
| Revenue growth (YoY) | +16.7% | +10.1% |
| Gross margin | 29.6% | 43.2% |
| Operating margin | -162.9% | -15.9% |
| Net margin | -182.8% | -14.9% |
| Net income | -$3.74M | -$108.03M |
| EPS (Diluted) | -$0.76 | n/a |
| Operating cash flow | -$1.92M | $5.23M |
| Free cash flow | n/a | -$21.78M |
| Cash & equivalents | $1.03M | $159.62M |
| Total assets | $4.14M | $1.36B |
| Total liabilities | $4.16M | $523.27M |
| Shareholders' equity | -$19.2K | $836.56M |
| Return on year-end equity | n/a | -12.9% |
| Shares outstanding | 5.44M | 128.15M |
Revenue, most recent five fiscal years
| Fiscal year | 20/20 Biolabs, Inc. | NeoGenomics Inc |
|---|---|---|
| Latest | $2.05M Ended 2025-12-31 | $727.33M Ended 2025-12-31 |
| 1 year earlier | $1.75M Ended 2024-12-31 | $660.57M Ended 2024-12-31 |
| 2 years earlier | n/a | $591.64M Ended 2023-12-31 |
| 3 years earlier | n/a | $509.73M Ended 2022-12-31 |
| 4 years earlier | n/a | $484.33M Ended 2021-12-31 |